Skip to main content
SVBI logo

SVBI — Investor Relations & Filings

Ticker · 1786 ISIN · TW0001786002 TW Manufacturing
Open in API
Filings indexed 1,687 across all filing types
Latest filing 2022-03-23 Fund Information / Fact…
Country TW Taiwan
Listing TW 1786

About SVBI

www.scivision.com.tw

SciVision Biotech Inc. is a specialized developer and manufacturer of advanced medical devices, focusing on the research and production of hyaluronic acid (HA) products. The company leverages its proprietary Crosslinked Hyaluronic Acid Platform (CHAP) technology to create high-performance solutions across multiple medical disciplines. Its core product portfolio includes subcutaneous fillers for facial aesthetics, intra-articular injections for orthopedic joint care, anti-adhesion gels for surgical applications, and vesical instillation solutions for urological treatments. By integrating specialized R&D capabilities with precision manufacturing, SciVision Biotech provides medical-grade HA applications designed to improve patient outcomes in aesthetics and therapeutic recovery. The company is committed to scientific innovation and the expansion of its patented technology to meet diverse clinical needs in the global healthcare market.

Recent filings

Filing Released Lang Actions
110年度毛利率
Fund Information / Factsheet Classification · 90% confidence The document is very short (378 characters) and contains a simple table of annual revenue, cost, gross profit, and gross margin percentages for two years (109 and 110). It includes a note about updating the report annually on April 1 and a comment about explaining significant changes in gross margin. There is no detailed financial statement, no narrative management discussion, no regulatory certification, no voting results, no legal or governance information, and no mention of a specific report being attached or published. The content resembles a brief financial summary or factsheet rather than a full annual or interim report. Given the brevity and nature of the data, it fits best as a Fund Information / Factsheet (FS) type document, which typically provides a brief summary of key financial figures and metrics.
2022-03-23 Chinese
110年度營益分析
Interim / Quarterly Report Classification · 95% confidence The document contains financial data presented by quarter and year, including revenue, gross margin, operating profit margin, pre-tax profit margin, and after-tax profit margin. The data covers multiple fiscal years and quarters, indicating a comprehensive financial report for periods shorter than a full fiscal year. The document length is 1038 characters, which is relatively short but contains substantive financial data rather than just an announcement or certification. The content aligns with an Interim / Quarterly Report (IR) as it provides detailed financial metrics for quarterly and half-year periods, not just a summary or announcement. Therefore, the document is best classified as an Interim / Quarterly Report (IR). FY 2021
2022-03-23 Chinese
110年第4季權益變動表
Interim / Quarterly Report Classification · 90% confidence The document contains detailed tables of consolidated equity changes for a company, including items such as common stock capital, capital surplus, legal surplus reserve, special surplus reserve, undistributed earnings, retained earnings, foreign currency translation adjustments, and total equity. The data is presented for the current period and the previous year, with amounts in thousands of New Taiwan Dollars. This type of detailed financial data on equity changes is typical of a financial statement or part of a comprehensive financial report. The document length is 3636 characters, which is relatively short but contains substantive financial data rather than just an announcement or a certification. There is no indication that this is a standalone audit report, management change announcement, or other specific category. It is not a brief factsheet or a presentation. The content aligns with a financial report that includes actual financial data for a period shorter than a full fiscal year or a quarterly/interim report. Given the detailed financial data and the period references (current and last year), this document best fits the category of an Interim / Quarterly Report (IR). FY 2021
2022-03-23 Chinese
公告本公司董事會通過110年度合併財務報告
Regulatory Filings Classification · 95% confidence The document is a short announcement (898 characters) from a company named 科妍, dated 111/03/23 (Taiwan calendar, likely 2022/03/23 Gregorian), reporting that the board of directors has approved the consolidated financial report for the fiscal year 110 (2021). It includes summarized financial data such as revenue, gross profit, operating profit, net profit, EPS, total assets, liabilities, and equity for the full year 110/01/01 to 110/12/31. The document is brief and does not contain the full financial statements or detailed analysis, but rather a summary and notification of board approval. It fits the pattern of a Regulatory Filing (RNS) as it is a formal announcement of the approval of the annual consolidated financial report, not the full Annual Report (10-K) itself. The document is not a report publication announcement (RPA) because it does not mention the report being attached or available elsewhere, but is a direct announcement of the board's approval and key financial figures.
2022-03-23 Chinese
111年2月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document is a brief financial disclosure from a company named 科妍, providing information about the absence of fund loans and endorsement guarantees for the current and previous months, with amounts stated as zero. The content is very short (601 characters) and consists mainly of tabular data about financial guarantees and loans, without any detailed financial statements, management discussion, or regulatory certifications. It does not contain any narrative or detailed financial analysis typical of annual or interim reports. It also does not announce any voting results, management changes, or legal proceedings. Given the brevity and nature of the data, this document fits best as a Regulatory Filing (RNS), which is a fallback category for miscellaneous regulatory disclosures that do not fit other specific categories.
2022-03-10 Chinese
111年2月營業收入
Fund Information / Factsheet Classification · 95% confidence The document is a brief financial summary report showing monthly and cumulative net operating revenue figures for a company named 科妍 for the period 民國111年02月 (February 2022). It includes percentage changes compared to the previous year and explanatory notes about accounting standards and reporting practices. The document length is only 762 characters, which is very short and contains no detailed financial statements or comprehensive analysis. It appears to be a brief factsheet or summary of key financial data rather than a full report or announcement. Therefore, it fits best into the category of Fund Information / Factsheet (FS), which is defined as a brief (1-2 page) summary of key company facts and financials.
2022-03-10 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.